Weight-normalized norepinephrine dosing and apparent BMI-dependent vasopressin responsiveness - Takeaways - MDSpire

Weight-normalized norepinephrine dosing and apparent BMI-dependent vasopressin responsiveness

  • By

  • Pedro D. Wendel-Garcia

  • Sebastian Morales

  • Paulo Melo

  • Greta Emilia Kiavialaitis

  • Peter Wohlrab

  • Ricardo Castro

  • Edda Tschernko

  • Glenn Hernández

  • Eduardo Kattan

  • April 14, 2026

  • 0 min

Share

  • 1

    Obese patients with septic shock show a reduced norepinephrine-sparing response to vasopressin, indicating potential physiological resistance.

  • 2

    Norepinephrine exposure normalized to body weight may introduce bias, affecting the interpretation of vasopressor responsiveness in obese patients.

  • 3

    Weight-normalized norepinephrine dosing could lead to inaccurate clinical severity assessments and delays in treatment escalation for obese patients.

  • 4

    Time-dependent pharmacokinetics of vasopressin may contribute to observed differences in norepinephrine trajectories in obese patients.

  • 5

    Evaluating norepinephrine exposure in absolute units may clarify the relationship between body mass index and vasopressor response.

Original Source(s)

Weight-normalized norepinephrine dosing and apparent BMI-dependent vasopressin responsiveness

  • by Pedro D. Wendel-Garcia, Sebastian Morales, Paulo Melo, Greta Emilia Kiavialaitis, Peter Wohlrab, Ricardo Castro, Edda Tschernko, Glenn Hernández, Eduardo Kattan

  • April 14, 2026

Related Content

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.